4//SEC Filing
Mellon Family Investment Co V 4
Accession 0000899243-19-013260
CIK 0001563880other
Filed
May 12, 8:00 PM ET
Accepted
May 13, 5:03 PM ET
Size
12.6 KB
Accession
0000899243-19-013260
Insider Transaction Report
Form 4
Mellon Family Investment Co V
10% Owner
Transactions
- Conversion
Series C Preferred Stock
2019-05-09−1,908,450→ 0 total→ Common Stock (222,816 underlying) - Other
Common Stock
2019-05-09+24,340→ 247,156 total - Purchase
Common Stock
2019-05-09$10.00/sh+100,000$1,000,000→ 347,156 total - Conversion
Common Stock
2019-05-09+222,816→ 222,816 total
MFIC V, LLC
10% Owner
Transactions
- Conversion
Common Stock
2019-05-09+222,816→ 222,816 total - Other
Common Stock
2019-05-09+24,340→ 247,156 total - Purchase
Common Stock
2019-05-09$10.00/sh+100,000$1,000,000→ 347,156 total - Conversion
Series C Preferred Stock
2019-05-09−1,908,450→ 0 total→ Common Stock (222,816 underlying)
Footnotes (3)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]MFIC V, LLC, the general partner of Mellon Family Investment Company V, has sole voting and investment control with respect to shares of the Issuer's Common Stock held by Mellon Family Investment Company V.
- [F3]Consists of shares transferred to Mellon Family Investment Company V by TPG Biotechnology Partners III, L.P. in connection with the closing of the Issuer's initial public offering.
Documents
Issuer
Trevi Therapeutics, Inc.
CIK 0001563880
Entity typeother
IncorporatedPA
Related Parties
1- filerCIK 0001774956
Filing Metadata
- Form type
- 4
- Filed
- May 12, 8:00 PM ET
- Accepted
- May 13, 5:03 PM ET
- Size
- 12.6 KB